Clinical Research Of The Efficacy And Safety Of Transurethral Greenlight Laser Vaporization Of The Prostate For Benign Prostatic Hyperplasia

Objective:To evaluate the efficacy and safety of greenlight laser vaporization of the prostate (PVP) by comparing with transurethral plasmakinetic resection of the prostate (PKRP) for benign prostatic hyperplasia.Methods:Among the patients with BPH treated in our hospital from Dec. 2009 to Sep.2010,70 cases were included in our study. A randomized, single blind trail was performed to divide all cases into two groups. Thirty-five patients were assigned into PVP group (experimental group), and the other thirty-five patients were in PKRP group (control group). All the patients returned to our hospital and underwent reexamination which is administered by especially appointed staff at the third month after hospital discharge. We documented the clinical data of pre-operation, hospital discharge and 3 months later by means of the case report form with items of international prostate symptom score (IPSS), quality of life (QOL), male sexual function 4-item (MSF-4), operation time, loss of blood, irrigation volume, electrolyte and complications etc. All statistical analyses and assessment were performed with SPSS software (version 13.0).Results:A total of 11 patients were lost to follow up,5 cases in PVP group and 6 cases in PKRP group, respectively. There was no significant difference between the two groups in the data of preoperative situations, operation time, irrigation volume, lab tests, hospital stays, catheterization time and irrigation time (P>0.05). The loss of blood of the PVP group was less than that of the PKRP group (P<0.05). IPSS, QOL, Qmax,Qave in both groups were remarkably improved. There were 2 cases of anterior urethral strictures (7.0%) in PVP group and 3 cases (10.0%) in PKRP group respectively (P>0.05). There were no changes of sexual function before and after surgeries of all patients.Conclusion:PVP is a safe and efficient operative procedure for BPH, prior to PKRP for less loss of blood in the process of sugery while smilar in short-term (within three months) safety and efficacy.The long-term validity is necessary to be evaluated forward.